Chemotherapy versus support cancer treatment in advanced gastric cancer: A meta-analysis

Brazilian Journal of Medical and Biological Research

Volumn 39, Issue 4, 2006, Pages 431-440

  Casaretto, L ^a   Sousa, P L R ^a   Mari, J J ^a  

^a CATHOLIC UNIVERSITY OF PELOTAS   (Brazil)

Author keywords

Cancer support treatment; Chemotherapy; Combined Atineoplastic therapy; Gastric cancer; Meta analysis; Systematic review

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; AGE DISTRIBUTION; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; META ANALYSIS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; QUALITY OF LIFE; REVIEW; SEX DIFFERENCE; STOMACH ADENOCARCINOMA; SURVIVAL RATE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW;

SYRINGA;

EID: 33645823559     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2006000400002     Document Type: Review

References (27)

1. Instituto Nacional do Câncer (INCA). http://www.inca.org.br. Accessed February 12, 2004.
2. Murad AM, Santiago FE, Petroianu A et al. (1993). Modified therapy with fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer, 72: 37-41.
3. Pyrhonen S, Kuitunen T, Nyandoto P et al. (1995). Randomized comparison of fluorouracil, epidoxorubicin, and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. British Journal of Cancer, 71: 587-591.
4. Glimelius B, Ekstrom K, Hoffman K et al. (1997). Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Annals of Oncology, 8: 163-168.
5. Dent DM, Werner ID, Novis B et al. (1979). Prospective randomized trial of combined oncological therapy for gastric carcinoma. Cancer, 44: 385-391.
6. Wils J (1996). The treatment of advanced gastric cancer. Seminars in Oncology, 23: 397-399.
7. World Health Organization (1979). Handbook for Reporting Results of Cancer Treatment. WHO offset publication No. 48. World Health Organization, Geneva, Switzerland.
8. Bireme. http://www.bireme.br. Accessed April 10, 2004.
9. Cox DR (1972). Regression models and life tables. Journal of the Royal Statistical Society, 34: 187-220.
10. Oken MM (1982). Toxicity and response criteria of the Easten Cooperative Oncology Group. American Journal of Clinical Oncology, 5: 649-651.
11. Lopes P (1999). Probabilidades, a Estatistica. Reichmann & Affonso Editores, São Paulo, SP, Brazil.
12. Norell S & Ahlbom A (1990). Introduction to Modern Epidemiology. Foreword by Kenneth Rothman. ISBN 0-917227-06-9. Epidemiology Resources Inc., Chestnut Hill, MA, USA.
13. Fletcher RH (1996). Epidemiologia Clínica, Artes Médicas. 3rd edn. Artes Médicas, Porto Alegre, RS, Brazil.
14. Kirkwood BR (1994). Essentials of Medical Statistics. Blackwell Science, Oxford, UK.
15. Kingston RD, Ellis DJ, Powell J et al. (1978). The West Midland gastric carcinoma chemotherapy trial: planning and results. Clinical Oncology, 4: 55-69.
16. Park JO, Chung HC, Cho JY et al. (1997). Retrospective comparison of infusional 5-fluorouracil, doxorubicin and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer. American Journal of Clinical Oncology, 20: 484-489.
17. Glimelius B, Hoffman K, Graf W et al. (1994). Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Annals of Oncology, 5: 189-190.
18. Glimelius B, Hoffman K, Graf W et al. (1995). Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Annals of Oncology, 6: 267-274.
19. Abeloff MD (2000). Clinical Oncology. Chapter 60. 2nd edn. Churchill Livingstone, New York, 1545-1585.
20. O'Connell MJ (1985). Current status of chemotherapy for advanced pancreatic and gastric cancer. Journal of Clinical Oncology, 3:1032-1041.
21. Kohne CH (2000). Developments in the treatment of gastric cancer in Europe. Oncology, 14: 22-25.
22. Cornelis JH (1998). The gastric cancer treatment controversy. Journal of Clinical Oncology, 21: 2282-2287.
23. National Comprehensive Cancer Network. http://www.nccn.org/. Accessed February 2, 2004.
24. Ajani JA, Fairweather J, Dumas P et al. (1998). Phase II study of Taxol in patients with gastric carcinoma. Cancer Journal from Scientific American, 4: 269-274.
25. Moehler M, Haas U, Siabler J et al. (2003). Weekly treatment with irinotecan, folinic acid and infusionall 5-fluorouracil (IFL) in patients with advanced gastric cancer. Anticancer Drugs, 14: 645-650.
26. Cai H, Kong ZR & Chen HM (2002). Matrix metalloproteinase-2 and angiogenesis in gastric cancer. Ai Zheng, 21: 25-28.
27. Kono K, Takahashi A, Ichihara F et al. (2002). Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Research, 62: 5813-5817.